Skip to main content
NCBI home page
Oncology Letters logoLink to Oncology Letters
. 2020 Aug 28;20(5):171. doi: 10.3892/ol.2020.12028

Bufalin attenuates triple-negative breast cancer cell stemness by inhibiting the expression of SOX2/OCT4

Fei Chen 1,*, Li Zhu 2,*, Junyan Hu 1, Shujun Jiang 1, Hui Liu 1, Jie Zheng 1, Jiandong Wang 1, Feng Wang 1, Zhe Li 1,✉
PMCID: PMC7471667  PMID: 32934738

Abstract

Triple-negative breast cancer (TNBC) has the poorest prognosis among all types of breast cancer and there is yet no effective therapy. Chemotherapy is the traditional standard of care for patients with TNBC; however, treatment of TNBC with chemotherapy may lead to the enrichment of cancer stem cells (CSCs), which exhibitan enhanced capacity for self-renewal, tumor initiation and metastasis. The present study demonstrated that bufalin, a small molecular compound used in traditional Chinese medicine, exerted anticancer effects on a wide range of cancer cell lines, inhibited cell proliferation through inducing G2/M cell cycle arrest, and triggered apoptosis in the TNBC cell lines MDA-MB-231 and HCC-1937. Consistently, bufalin markedly suppressed TNBC growth in a cell line-derived xenograft model. More importantly, unlike common chemotherapeutic drugs, bufalin reduced the stemness of TNBC stem cells. A mechanistic study suggested that bufalin may suppress the proliferation of TNBC stem cells by inhibiting the expression of octamer-binding transcription factor 4 (OCT4) and sex determining region Y-box 2 (SOX2) in MDA-MB-231 and HCC-1937 cells. These results indicated that bufalin may hold promise as a therapeutic agent in TNBC, and its effects may be mediated through the SOX2/OCT4 axis.

Keywords: triple-negative breast cancer, cancer stem cells, bufalin

Introduction

Triple-negative breast cancer (TNBC) accounts for 12–17% of all breast cancers and it is a highly aggressive malignancy, displaying a high propensity for metastasis and the worst short-term prognosis among all types of breast cancer (1,2). At present, there are no available targeted therapy options due to the inherent heterogeneity of TNBC (3,4), and the standard of care includes surgery, radiotherapy and/or chemotherapy for both early- and advanced-stage disease. However, the majority of patients with TNBC will ultimately develop drug resistance, tumor relapse and/or metastasis (5–7).

In recent years, several trials investigating therapeutic combinations have led to promising advances in TNBC therapy (3,8). Zhang et al demonstrated that agents that inhibit cancer cell stemness may complement the antitumor activity of chemotherapy by eliminating chemo resistant cancer stem cells (CSCs) (9). CSCs are a small proportion of cancer cells that possess normal stem cell markers. Compared with non-CSCs, they exhibit lower sensitivity and higher degrees of resistance to drugs and irradiation (5,10). Furthermore, numerous chemotherapeutic agents have been found to increase the proportion of CSCs and increase the tumor-initiating potential of breast cancer cells in vitro and in vivo (11). Thus, CSCs are considered to be responsible for breast cancer recurrence and metastasis (12–14), and there is an urgent need to develop innovative and more effective therapeutic approaches that achieve a more durable response to TNBC treatment. TNBC treatment may be improved by identifying a single agent with bioactivities targeted at eliminating or inhibiting both CSCs and non-CSCs.

Toad skin has long been used for cancer therapy in traditional Chinese medical practice, and toad skin extract is currently widely used as a traditional Chinese medicine (15). Bufalin, a cardiotonic steroid isolated from toad venom, is an active compound that may be used for its functions in pain relief, myocardial contraction stimulation, blood pressure stimulation and anti-inflammation, among others (16). Since 2010, bufalin has been known for its anticancer effects on a wide range of cancer cell lines, including breast cancer cell lines (17–21). It has been reported that bufalin possesses the ability toinhibit cell proliferation, induce cell apoptosis, and inhibit metastasis and invasion of human cancer cells (10,17,21–24). Furthermore, bufalin may be used safely over an extended period of time without marked side effects (21). All these findings indicate that bufalin may be a promising candidate for anticancer treatment. However, it remains unknown whether bufalin can inhibit CSCs.

The transcription factor sex determining region Y-box 2 (SOX2) has been reported to be highly expressed in TNBC cell lines and patient tissues (25). High SOX2 levels are correlated with poor differentiation of TNBC and short survival time of the patients (25). The expression of octamer-binding transcription factor 4 (OCT4) was also found to be associated with worse prognosis of TNBC patients after surgery (26). Moreover, SOX2 may promote TNBC cell proliferation and metastasis in vitro as well as in vivo, suggesting that SOX2 acts as a tumor promoter in TNBC (27). However, the role of SOX2 and OCT4 in the regulation of CSCs in TNBC remains unclear.

The purpose of the present study was to investigate whether bufalin can inhibit the stemness of TNBC cells and elucidate the underlying mechanism.

Materials and methods

Cell culture and transient transfection

The TNBC cell lines MDA-MB-231 and HCC-1937 were obtained from the Cell Bank of the Representative Culture Preservation Committee of the Chinese Academy of Sciences. All the cells were cultured in DMEM supplemented with 10% FBS (HyClone; Cytiva) at 37°C in 5% CO2 and subcultured every 2–3 days. siRNA or negative control RNA were obtained from Shanghai GenePharma Co. Ltd. The cells were seeded in six-well plates at a density of 3×105 cells/well. The transfections were performed using Transfection Reagent (Polyplus Transfection SA) according to the manufacturer's instructions. The transfection efficiency was confirmed via quantitative PCR. For the spheroid formation assay, the cells were transfected with siRNA targeting SOX2 or OCT4 for 24 h prior to treatment with bufalin (0.5 µM).

Cell Counting Kit-8 (CCK-8) assay for cell proliferation

The MDA-MB-231 and HCC-1937 cells were plated in 96-well plates at a density of 3×103 cells/well and incubated at 37°C for 24, 48 or 72 h. At the end of the incubation period, CCK-8 reagent (Beyotime Institute of Biotechnology) was added to each well and incubated at 37°C for 1 h according to the manufacturer's instructions. After staining, the absorbance was measured at 570 nm (Multiskan Spectrum; Thermo Fisher Scientific, Inc.).

Cell apoptosis and cell cycle distribution analysis

Following incubation with 0.5 µM bufalin for 48 h, the MDA-MB-231 and HCC-1937 cells were harvested for PI staining or Annexin V-PI staining according to the manufacturer's instructions (Beyotime Institute of Biotechnology). Data acquisition and analysis were performed using a FACSCanto II Flow Cytometer (BD Biosciences). A total of 1×104 cells were scanned in each analysis. Each experiment was repeated at least three times.

Colony formation assay

Following treatment with 0.5 µM bufalin or vehicle, MDA-MB-231 and HCC-1937 cells were reseeded in 12-well plates at a density of 10,000 cells/well and cultured at 37°C to form natural colonies. After 7 days, the cells were washed with PBS 3 times and fixed with 4% paraformaldehyde for 20 min at room temperature. The fixed colonies were stained with 20% crystal violet solution at room temperature for 10 min and captured.

Western blot analysis

The cells were lysed in RIPA lysis buffer (Beyotime Institute of Biotechnology). Equal amounts of proteins (25 µg) were separated using 10% SDS-PAGE, transferred onto nitrocellulose membranes (Beyotime Institute of Biotechnology) and blocked with 5% non-fat milk for 1 h at room temperature. After incubation with an antibody specific for poly (ADP-ribose) polymerase (anti-PARP; 1:1,000; cat. no. 9532, Cell Signaling Technology, Inc.) for 2 h at room temperature, the blots were incubated with anti-rabbit secondary antibody (1:10,000; cat. no. 3900, Cell Signaling Technology, Inc.) for 2 h at room temperature and then detected by enhanced chemiluminescence (Beyotime Institute of Biotechnology). β-actin was used as a loading control.

In vivo tumorigenicity assays

MDA-MB-231 cells (2×106) were suspended in 100 µl PBS and injected into the lower flank of 14 4–6-weeks old nude mice housed in a room at 23–28°C and approximately 70% humidity, with an alternating 12 h light (from 7 a.m.)/dark cycle (from 7 p.m.) and free access to sterilized food and water. All experiment operations complied with laboratory animal ethics requirements approved by IACUC. Tumor diameter was measured with calipers. When the tumor diameter reached ~5 mm, bufalin (T1719; Shanghai Topscience Co., Ltd.) was injected into the tumor at a dose of 1 mg/kg three times per week (n=7), whereas control group animals were injected with an equal volume of DMSO (n=7). After 2 weeks, the tumors were weighed with an electronic balance. The animal experimental protocols were approved by the Ethics Committee of the University of Traditional Chinese Medicine.

Immunohistochemistry (IHC) staining

The xenograted tumors were fixed in 10% formalin at room temperature for 48 h and embedded in paraffin. Then, the paraffin blocks were cut into 4-mm sections and deparaffinized. Routine IHC staining for Ki-67 (1:100; Cell Signaling Technology, Inc.) was performed on the slidesandstaining for SOX2 (1:100; Proteintech, Inc.) or OCT4 (1:100; Proteintech, Inc.) was performed on the TNBC tissue microarray (Shanghai Outdo Biotech, Inc). Detection was performed using Ventana's UltraView diaminobenzidine (DAB) detection kit (P0202; Beyotime Institute of Biotechnology). Apoptotic cells were identified by TUNEL colorimetric staining according to the manufacturer's instructions (Roche Applied Science, Inc.). The tissue microarray (HBreD050Bc01), including 40 TNBC patient tissue samples was purchased from Shanghai Outdo Biotech Co., Ltd., and subjected to IHC staining

Spheroid formation assay

Approximately 500 viable single cells were plated on ultra-low attachment 96-well plates (Thermo Fisher Scientific, Inc.) and cultured in cell growth medium (Thermo Fisher Scientific, Inc.) with or without bufalin at a dose of 0.5 µM for 7 days. The number of spheroids was counted under an inverted microscope (IX51; Olympus Corporation) at a magnification of ×100.

Gene expression analysis

Total RNA was extracted from MB-231 and HCC-1937 cells using TRIzol®(Invitrogen; Thermo Fisher Scientific, Inc.). For reverse transcription-quantitative PCR (RT-qPCR) analysis, 1 µg total RNA was reverse-transcribed (37°C for 1 h and 70°C for 10 min) by using Superscript III RT (Invitrogen; Thermo Fisher Scientific, Inc.). qPCR was performed using the ABI PRISM 7300HT Sequence Detection System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The thermocycling conditions were as follows: 1 cycle at 95°C for 5 min, followed by 40 cycles at 95°C for 15 sec (denaturation), 60°C for 30 sec (annealing), 72°C for 30 sec (extension) and 72°C for 5 min (final extension). The relative expression level of each gene was calculated using the 2−∆∆Cq method (∆∆Cq=∆Cqbufalin-∆Cq) (28). The primers used for SOX2, OCT4, c-Myc, β-catenin, Nanog and β-actin are listed in Table SI.

Statistical analysis

For statistical analysis, Student's t-test was used for parametric variables. One-way ANOVA followed by Dunnett's test was used for comparisons among multiple groups. All tests were performed three times, and P<0.05 was considered to indicate statistically significant differences.

Results

Bufalin inhibits TNBC cell proliferation and induces apoptosis

To investigate the biological effect of bufalin in TNBC, in vitro assays were performed in MDA-MB-231 and HCC1937 cells using the dosages mentioned in previous studies (29,30). First, the CCK-8 assay was used to examine the effect of bufalin on cell proliferation. As shown in Fig. 1A, bufalin significantly inhibited the proliferation of both MDA-MB-231 and HCC1937 cells (P<0.05). Second, the antiproliferative effects of bufalin were further determined by colony formation assays, and the data revealed that the number and size of the colonies were markedly reduced by bufalin treatment (Fig. 1B). The effect of bufalin on the regulation of the tumor cell cycle was then assessed using FACS analysis. As shown in Fig. 1C and D, bufalin led to increased accumulation of cells in the G2/M phase of the cell cycle. Next, the apoptotic rates induced by bufalin were evaluated by flow cytometry, and our data demonstrated that bufalin triggered apoptosis of MDA-MB-231 and HCC1937 cells (Fig. 2A and B). Consistently, the induction of PARP, an apoptosis regulator, also confirmed this effect (Fig. 2C).

Figure 1.

Figure 1.

Open in a new tab

Bufalin inhibits TNBC cell proliferation in vitro. (A) The proliferation of MDA-MB-231 and HCC-1937 cells was measured by the Cell Counting Kit-8 assay following treatment with 0.5 µM bufalin or vehicle for the indicated times. The data are shown as mean ± standard deviation; Student's t-test *P<0.05. (B) Colony formation assays were performed on MDA-MB-231 and HCC1937 cells following treatment with vehicle, 0.5 or 1 µM bufalin for 7 days. (C and D) Quantitative cell cycle analysis. MDA-MB-231 and HCC-1937 cells were treated with vehicle or 0.5 µM bufalin for 48 h and cell cycle distribution was analyzed. (C) Representative cell cycle distribution following treatment of MDA-MB-231 and HCC1937 cells with 0.5 µM bufalin. (D) Quantitative analysis of the proportion of the cells in each phase of the cell cycle was performed from at least 10,000 cells per sample.

Figure 2.

Figure 2.

Open in a new tab

Bufalin induces apoptosis in triple-negative breast cancer cells. (A and B) Flow cytometry was used to determine the apoptotic rates of MDA-MB-231 and HCC-1937 cells following incubation with 0.5 µM bufalin or vehicle for 48 h. The data are shown as mean ± standard deviation; Student's t-test *P<0.05. (C) The protein expression levels of PARP were determined by western blot analysis followingtreatment of MDA-MB-231 and HCC-1937 cells with 0, 0.5 or 1 µM bufalin. PARP, poly(ADP-ribose) polymerase.

Bufalin suppresses TNBC growth in vivo

After confirming that bufalin inhibits cell proliferation and enhances apoptosis in vitro, it was examined whether bufalin can inhibit breast cancer growth in a xenograft TNBC model. As shown in Fig. 3A and B, bufalin significantly decreased the tumor volume and weight compared with vehicle control. Ki-67 and TUNEL staining were also performed on paraffin sections of tumor samples collected from xenografts. A reduction in Ki-67 expression and an increase in apoptosis were observed in tumors treated with bufalin compared with those treated with vehicle (Fig. 3C and D). These results further confirmed the therapeutic effect of bufalin in TNBC.

Figure 3.

Figure 3.

Open in a new tab

Bufalin suppresses triple-negative breast cancer growth in vivo. (A) In order to establish a xenograft nude mouse model, MDA-MB-231 cells were inoculated into the lower flank of nude mice. When the tumor diameter reached ~5 mm, bufalin was injected into the tumor at a dose of 1 mg/kg three times per week, whereas the control group was injected with an equal volume of DMSO. (B) The tumor weight was analyzed by the two-samples t-test. The data are shown as mean ± standard deviation; Student's t-test *P<0.05. (C) Representative images of H&E (left) and immunohistochemistryKi-67 (right) staining of tissue samples from each group. Images were captured at a magnification of ×200. (D) Representative TUNEL staining images. The apoptotic cells appear as TUNEL-positive. Images were captured at a magnification of ×200. H&E, hematoxylin and eosin.

Bufalin inhibits the self-renewal of TNBC stem cells

To explore whether bufalin attenuates the stemness of TNBC cells, a spheroid formation assay was performed. MDA-MB-231 and HCC1937 cells exhibited a reduced capacity to form spheroids when treated with 0.5 µM bufalin compared with control cells (Fig. 4A and B). Furthermore, the proportion of sphere-forming cells was determined by performing a limiting dilution analysis of cells incubated with or without bufalin, and the results demonstrated that the proportion of MDA-MB-231 and HCC1937 cells forming spheroids was significantly decreased by bufalin (P<0.05; Fig. 4C and D). These data indicated that bufalin effectively suppressed the self-renewal of TNBC stem cells.

Figure 4.

Figure 4.

Open in a new tab

Bufalin inhibits the ability of triple-negative breast cancercells to form spheroids. (A) Representative images of MDA-MB-231 and HCC1937 spheroids grown in Matrigel incubated with 0.5 µM bufalin or vehicle. (B) Numbers of spheroids incubated with vehicle or bufalin; the data are shown as mean ± standard deviation; Student's t-test *P<0.05. (C and D) Tumor-initiating cell (T-IC) frequency from an in vitro limiting dilution assay. *P<0.05.

Bufalin attenuates TNBC cell stemness via suppressing SOX2/OCT4

To elucidate the mechanisms through which bufalin attenuates the stem cell characteristics of TNBC cells, RT-qPCR analysis was performed to analyze the expression level of stemness-related genes following bufalin treatment, as shown in Fig. 5A and B. The expression levels OCT4 and SOX2 were found to be significantly downregulated following treatment with bufalin (P<0.05). To further confirm whether bufalin attenuates the stemness characteristics of TNBC cells by inhibiting SOX2/OCT4 expression, MDA-MB-231 or HCC1937 cells were transfected with siRNAs targeting OCT4 and SOX2, followed by a spheroid formation assay. The results demonstrated that the ability of TNBC cells to form spheroids was not affected by bufalin after SOX2 or OCT4 expression interference (P<0.05), suggesting that bufalin may attenuate the stemness of TNBC cells via downregulating the stemness-associated factors SOX2/OCT4 (Fig. 5C-E). In addition, SOX2/OCT4 protein expression was examined in 40 tissue samples from patients with TNBC. As expected, most TNBC tissues exhibited upregulated SOX2 (27/40) and OCT4 (30/40) expression (Fig. 5F).

Figure 5.

Figure 5.

Open in a new tab

Bufalin attenuates the stem cell characteristics of TNBC cells via suppressing SOX2/OCT4. Genes expression levels were determined by reverse transcription-quantitative PCR analysis and normalized to the GAPDH level. (A and B) mRNA levels of OCT4, SOX2, c-Myc, β-catenin and Nanog in the indicated groups and (C) mRNA levels of OCT4 and SOX2 following transfection with siRNAs targeting OCT4 or SOX2. (D and E) Number of spheroids resulting from incubation with vehicle or bufalin following transfection with siRNAs targeting OCT4 or SOX2; the data are shown as mean ± standard deviation; Student's t-test *P<0.05. (F) The expression of SOX2 and OCT4 in 40 TNBC patient tissues was determined by routine immunohistochemical examination. The pictures were taken via microscopy at a magnification of 400X. Brown font indicates downregulation and black font indicates upregulation. The number of tumor tissues with low (13) or high (27) SOX2 and low (10) or high (30) Oct4 expression among 40 TNBC tissues were shown under each set of panels. TNBC, triple-negative breast cancer; OCT4, octamer-binding transcription factor 4; SOX2, sex determining region Y-box 2.

Discussion

Bufalin is a potential polygenic and multi target anticancer agent (22). Numerous studies have reported that bufalin can induce cell cycle arrest and apoptosis and even trigger autophagic cell death in various human cancer cell lines (17,31,32). Furthermore, bufalin can suppress cancer growth and metastasis by inhibiting distinct cancer-associated signaling pathways, including transforming growth factor-β, phosphoinositide 3-kinase/AKT, Wnt/β-catenin and mitogen-activated protein kinase/extracellular signal-regulated kinase pathways in different types of cancer (22,23,33,34). Consistent with these studies, the results of the present study demonstrated that bufalin can inhibit TNBC growth by inducing G2/M cell cycle arrest and promoting apoptosis of MDA-MB-231 or HCC1937 cells. The decreased proportion of cells in the G1/G0 phase of the cell cycle may be explained by increased S entry or decreased G1/G0 entry. The data in Fig. 1A and B demonstrated that bufalin suppressed the proliferation of TNBC cellsby inducing G2/S arrest and causing decreased G1/G0 entry, which explains the decreased proportion of G1/G0 phase cells.

At present, cytotoxic chemotherapy remains the mainstay of treatment for patients with TNBC, as these patients respond poorly to other types of therapies (35,36). However, following chemotherapy, tumor recurrence or metastasis may develop from chemo resistant preexisting CSCs or from resilient cancer cells that eventually acquire CSC properties (11,37,38). Conventional chemotherapeutic agents target proliferating cells to induce their apoptosis, while they exert little effect on CSCs (39). It was recently demonstrated that cancer cells may acquire stemness characteristics following chemotherapy (40). Moreover, a recent study reported that agents inhibiting cancer cell stemness may complement the antitumor activity of chemotherapy in eradicating breast cancer patient-derived xenografts (9). Therefore, it is crucial to identify novel agents that can effectively target both CSCs and non-CSCs. In the present study, it was examined whether bufalin could inhibit TNBC cell stemness. The spheroid formation assay results demonstrated that bufalin reduced the ability of MDA-MB-231 and HCC-1937 cells to form spheroids. Other previous studies suggested that enhancement of CSCs may be detected following activation of stemness-associated factors, such as SOX2, OCT4, β-catenin, c-Myc and Nanog, in cancer cells (41–44). To investigate the molecular mechanism underlying the bufalin-mediated stemness reduction, the mRNA expression levels of SOX2, OCT4, c-Myc, β-catenin and Nanog were examined. The results demonstrated that SOX2 and OCT4 were significantly downregulated following bufalin treatment. Furthermore, the ability of MDA-MB-231 and HCC-1937 cells to form spheroids was not affected by bufalin in cells transfected with siRNAs targeting SOX2 or OCT4. All these data indicate that bufalin successfully inhibited stemness in MDA-MB-231 and HCC-1937 cells.

In conclusion, bufalin was shown to not only inhibit the proliferation and induce apoptosis in TNBC cells, but was also able to significantly attenuate the stemness of TNBC cells. However, further studies are warranted to confirm whether bufalin may be of value for preventing cancer recurrence or chemo resistance.

Supplementary Material

Supporting Data

Acknowledgements

Not applicable.

Glossary

Abbreviations

TNBC

triple-negative breast cancer

CSC

cancer stem cell

OCT4

octamer-binding transcription factor 4

SOX2

sex determining region Y-box 2

Funding

The present study was supported by a grant from the twelfth five-year key subject (Integrated Chinese and Western Medicine and General practice training of Traditional Chinese Medicine) of Traditional Chinese Medicine of State Administration of Traditional Chinese medicine, the Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (grant no. 2017315A) and Siming Youth Foundation of Shanghai Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (grant no. SGKJ-201717)..

Availability of materials and data

All data that support the findings of this study are available from the corresponding author to the researchers upon reasonable request.

Authors' contributions

FC, LZ and ZL conceived and designed the study. FC, LZ, ZL, SJ, HL, JZ, JW, FW performed the experiments. FC, LZ, JH and ZL analyzed the data. FC, LZ, SJ and ZL interpreted results of experiments. FC and LZ prepared figures. FC, LZ, SJ and ZL drafted the manuscript. FC, LZ, JH and ZL edited the manuscript. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

The animal experimental protocols were approved by the Ethics Committee of the University of Traditional Chinese Medicine.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

  • 1.William DF, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Eng J Med. 2010;363:1938–1948. doi: 10.1056/NEJMra1001389. [DOI] [PubMed] [Google Scholar]
  • 2.Cinkaya A, Akin M, Sengul A. Evaluation of treatment outcomes of triple-negative breast cancer. J Cancer Res Ther. 2016;12:150–154. doi: 10.4103/0973-1482.154000. [DOI] [PubMed] [Google Scholar]
  • 3.Gu G, Dustin D, Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016;31:97–103. doi: 10.1016/j.coph.2016.11.005. [DOI] [PubMed] [Google Scholar]
  • 4.Lee A, Djamgoz MBA. Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies. Cancer Treat Rev. 2018;62:110–122. doi: 10.1016/j.ctrv.2017.11.003. [DOI] [PubMed] [Google Scholar]
  • 5.Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 2009;106:13820–13825. doi: 10.1073/pnas.0905718106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Kimbung S, Markholm I, Bjöhle J, Lekberg T, von Wachenfeldt A, Azavedo E, Saracco A, Hellstrom M, Veerla S, Paquet E, et al. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. Int J Cancer. 2018;142:618–628. doi: 10.1002/ijc.31070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Bonotto M, Gerratana L, Poletto E, Driol P, Giangreco M, Russo S, Minisini AM, Andreetta C, Mansutti M, Pisa FE, et al. Measures of outcome in metastatic breast cancer: Insights from a real-world scenario. Oncologist. 2014;19:608–615. doi: 10.1634/theoncologist.2014-0002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Wali VB, Langdon CG, Held MA, Platt JT, Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF, Hatzis C. Systematic drug screening identifies tractable targeted combination therapies in triple-negative breast cancer. Cancer Res. 2017;77:566–578. doi: 10.1158/0008-5472.CAN-16-1901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zhang S, Zhang H, Ghia EM, Huang J, Wu L, Zhang J, Lam S, Lei Y, He J, Cui B, et al. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. Proc Natl Acad Sci. 2019;116:1370–1377. doi: 10.1073/pnas.1816262116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Pavlopoulou A, Oktay Y, Vougas K, Louka M, Vorgias CE, Georgakilas AG. Determinants of resistance to chemotherapy and ionizing radiation in breast cancer stem cells. Cancer Lett. 2016;380:485–493. doi: 10.1016/j.canlet.2016.07.018. [DOI] [PubMed] [Google Scholar]
  • 11.Dittmer J. Breast cancer stem cells: Features, key drivers and treatment options. Semin Cancer Biol. 2018;53:59–74. doi: 10.1016/j.semcancer.2018.07.007. [DOI] [PubMed] [Google Scholar]
  • 12.Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, Klein C, Saini M, Bäuerle T, Wallwiener M, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol. 2013;31:539–544. doi: 10.1038/nbt.2576. [DOI] [PubMed] [Google Scholar]
  • 13.Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells-what challenges do they pose? Nat Rev Drug Discov. 2014;13:497–512. doi: 10.1038/nrd4253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Peitzsch C, Tyutyunnykova A, Pantel K, Dubrovska A. Cancer stem cells: The root of tumor recurrence and metastases. Semin Cancer Biol. 2017;44:10–24. doi: 10.1016/j.semcancer.2017.02.011. [DOI] [PubMed] [Google Scholar]
  • 15.Qi F, Li A, Zhao L, Inagaki Y, Wang D, Cui X, Gao B, Kokudo N, Nakata M, Tang W. Cinobufacini, an aqueous extract from Bufobufogargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. J Ethnopharmacol. 2010;128:654–661. doi: 10.1016/j.jep.2010.02.022. [DOI] [PubMed] [Google Scholar]
  • 16.Calderón-Montaño JM, Burgos-Morón E, Orta ML, Maldonado-Navas D, García-Domínguez I, López-Lázaro M. Evaluating the cancer therapeutic potential of cardiac glycosides. Biomed Res Int. 2014;2014:794930. doi: 10.1155/2014/794930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Lan YL, Lou JC, Jiang XW, Wang X, Xing JS, Li S, Zhang B. A research update on the anticancer effects of bufalin and its derivatives. Oncol Lett. 2019;17:3635–3640. doi: 10.3892/ol.2019.10062. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Cheng CS, Wang J, Chen J, Kuo KT, Tang J, Gao H, Chen L, Chen Z, Meng Z. New therapeutic aspects of steroidal cardiac glycosides: The anticancer properties of Huachansu and its main active constituent bufalin. Cancer Cell Int. 2019;19:92. doi: 10.1186/s12935-019-0806-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Song X, Zhang C, Zhao M, Chen H, Liu X, Chen J, Lonard DM, Qin L, Xu J, Wang X, et al. Steroid receptor coactivator-3 (SRC-3/AIB1) as a novel therapeutic target in triple negative breast cancer and its inhibition with a phospho-bufalin prodrug. PLoS One. 2015;10:e0140011. doi: 10.1371/journal.pone.0140011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wang Q, Li C, Zhu Z, Teng Y, Che X, Wang Y, Ma Y, Wang Y, Zheng H, Liu Y, Qu X. miR-155-5p antagonizes the apoptotic effect of bufalin in triple-negative breast cancer cells. Anticancer Drugs. 2016;27:9–16. doi: 10.1097/CAD.0000000000000296. [DOI] [PubMed] [Google Scholar]
  • 21.Takai N, Kira N, Ishii T, Yoshida T, Nishida M, Nishida Y, Nasu K, Narahara H. Bufalin, a traditional oriental medicine, induces apoptosis in human cancer cells. Asian Pac J Cancer Prev. 2012;13:399–402. doi: 10.7314/APJCP.2012.13.1.399. [DOI] [PubMed] [Google Scholar]
  • 22.Wang J, Xia Y, Zuo Q, Chen T. Molecular mechanisms underlying the antimetastatic activity of bufalin. Mol Clin Oncol. 2018;8:631–636. doi: 10.3892/mco.2018.1591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zhao L, Liu S, Che X, Hou K, Ma Y, Li C, Wen T, Fan Y, Hu X, Liu Y, Qu X. Bufalin inhibits TGF-β-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGF-β receptors. Int J Mol Med. 2015;36:645–652. doi: 10.3892/ijmm.2015.2268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Feng Y, Chen Y, Meng Y, Cao Q, Liu Q, Ling C, Wang C. Bufalin suppresses migration and invasion of hepatocellular carcinoma cells elicited by poly (I:C) therapy. Oncoimmunology. 2018;7:e1426434. doi: 10.1080/2162402X.2018.1426434. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yao GD, Niu YY, Chen KX, Meng HX, Yao GD, Song HT, Tian ZN, Geng JS, Feng MY. SOX2 gene expression and its role in triple negative breast cancer tissues. J Biol Regul Homeost Agents. 2018;32:1399–1406. [PubMed] [Google Scholar]
  • 26.Zhang JM, Wei K, Jiang M. OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer. Breast Cancer. 2018;25:447–455. doi: 10.1007/s12282-018-0844-x. [DOI] [PubMed] [Google Scholar]
  • 27.Liu P, Tang H, Song C, Wang J, Chen B, Huang X, Pei X, Liu L. SOX2 promotes cell proliferation and metastasis in triple negative breast cancer. Front Pharmacol. 2018;9:942. doi: 10.3389/fphar.2018.00942. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402–408. doi: 10.1006/meth.2001.1262. [DOI] [PubMed] [Google Scholar]
  • 29.Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L, Song N, Teng Y, Liu Y. Downregulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol. 2012;138:1279–1289. doi: 10.1007/s00432-012-1204-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Clifford RJ, Kaplan JH. Human breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells. PLoS One. 2013;8:e84306. doi: 10.1371/journal.pone.0084306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Hsu CM, Tsai Y, Wan L, Tsai FJ. Bufalin induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells. Int J Oncol. 2013;43:338–348. doi: 10.3892/ijo.2013.1942. [DOI] [PubMed] [Google Scholar]
  • 32.Li M, Yu X, Guo H, Sun L, Wang A, Liu Q, Wang X, Li J. Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells. Tumour Biol. 2014;35:2461–2471. doi: 10.1007/s13277-013-1326-6. [DOI] [PubMed] [Google Scholar]
  • 33.Gai JQ, Sheng X, Qin JM, Sun K, Zhao W, Ni L. The effect and mechanism of bufalin on regulating hepatocellular carcinoma cell invasion and metastasis via Wnt/β-catenin signaling pathway. Int J Oncol. 2016;48:338–348. doi: 10.3892/ijo.2015.3250. [DOI] [PubMed] [Google Scholar]
  • 34.Qian L, Su H, Wang G, Li B, Shen G, Gao Q. Anti-tumor activity of bufalin by inhibiting c-MET mediated MEK/ERK and PI3K/AKT signaling pathways in gallbladder cancer. J Cancer. 2020;11:3114–3123. doi: 10.7150/jca.38393. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Early Breast Cancer Trialists' Collaborative Group (EBCTCG), corp-author Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, Cutter D, Darby S, McGale P, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379:432–444. doi: 10.1016/S0140-6736(11)61625-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014;384:164–172. doi: 10.1016/S0140-6736(13)62422-8. [DOI] [PubMed] [Google Scholar]
  • 37.Adorno-Cruz V, Kibria G, Liu X, Doherty M, Junk DJ, Guan D, Hubert C, Venere M, Mulkearns-Hubert E, Sinyuk M, et al. Cancer stem cells: Targeting the roots of cancer, seeds of metastasis, and sources of therapy resistance. Cancer Res. 2015;75:924–929. doi: 10.1158/0008-5472.CAN-14-3225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, Lee YK, Kwon HY. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:5416923. doi: 10.1155/2018/5416923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Cojoc M, Mabert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: Cellular and molecular mechanisms. Semin Cancer Biol. 2015;31:16–27. doi: 10.1016/j.semcancer.2014.06.004. [DOI] [PubMed] [Google Scholar]
  • 40.Batlle E, Clevers H. Cancer stem cells revisited. Nat Med. 2017;23:1124–1134. doi: 10.1038/nm.4409. [DOI] [PubMed] [Google Scholar]
  • 41.Tirino V, Desiderio V, Paino F, De Rosa A, Papaccio F, La Noce M, Laino L, De Francesco F, Papaccio G. Cancer stem cells in solid tumors: An overview and new approaches for their isolation and characterization. FASEB J. 2013;27:13–24. doi: 10.1096/fj.12-218222. [DOI] [PubMed] [Google Scholar]
  • 42.Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, Guerra M, Guo W, Xu X. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene. 2012;31:4898–4911. doi: 10.1038/onc.2011.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Moon JH, Kwon S, Jun EK, Kim A, Whang KY, Kim H, Oh S, Yoon BS, You S. Nanog-induced dedifferentiation of p53-deficient mouse astrocytes into brain cancer stem-like cells. Biochem Biophys Res Commun. 2011;412:175–181. doi: 10.1016/j.bbrc.2011.07.070. [DOI] [PubMed] [Google Scholar]
  • 44.Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature. 2004;431:1112–1117. doi: 10.1038/nature03043. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Data
Supplementary_Data.pdf (37KB, pdf)

Articles from Oncology Letters are provided here courtesy of Spandidos Publications

RESOURCES